Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.
about
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Canakinumab for the treatment of familial Mediterranean fever.The burgeoning field of innate immune-mediated disease and autoinflammation.Interleukin-1 Blockade: An Update on Emerging Indications.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Autoinflammatory Diseases with Periodic Fevers.Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome.Tumor necrosis factor-associated periodic syndrome in adults.TNF-α potentiates uric acid-induced interleukin-1β (IL-1β) secretion in human neutrophils.Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.The classification, genetic diagnosis and modelling of monogenic autoinflammatory disordersIL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse
P2860
Q33710807-7006CBBD-EED7-4D8A-8092-3987540DE6B7Q38814103-AB20AB2F-C24B-437B-A7EE-CF02AFC464C8Q38865019-8D6F7952-68DE-4E2D-BD18-D5A3A7E14731Q38967233-EE9B5017-F660-4EA7-BA67-C3D9C4B8C68CQ39301613-DFE5B7B8-2761-4C8C-86D7-397BF036FC58Q39301708-B947B544-EBFC-4ECB-A7CF-C379D9879AAEQ39325689-10E29755-53BC-4F6C-81EB-C0DE3AE5889BQ39384980-1A0FC7BE-7991-4382-82F9-BB7D84997F22Q40057989-A6A31E17-F96A-4165-A91F-C88D96812672Q41929105-94F40529-9006-47E0-A30C-4D5B3796F3C3Q48022132-FEBC0D02-01B1-4C47-9C97-6EEC2467F7E5Q50152542-5C20DBE6-8309-42F7-901D-B365B160A01DQ57160539-5AF698AB-B025-4B9C-9421-30EF048D2849Q58562869-DB4E23C8-C4DC-46ED-A290-64C65FECD4B3
P2860
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
type
label
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
prefLabel
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
P2093
P2860
P1476
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
P2093
Alberto Martini
Antonio Speziale
Ken Abrams
Marco Cattalini
Marco Gattorno
Nicole Davis
Suraj G Bhansali
Vincent Tormey
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-209031
P407
P577
2016-06-07T00:00:00Z